News Articles and Montana BioScience Alliance Newsletters
The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies. Montana’s Inimmune recently made the top-20 list.
A Montana State University undergraduate has been admitted to a prestigious European graduate program where she will advance her research in disease prevention and other applications of the growing field of bioinformatics.
Beginning with cannabis, the Missoula, MT based company is creating a self-contained and portable product that can detect impairment in real-time. The product will be sold to law enforcement agencies, and businesses with safety-critical employees.
Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.
Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to Timing COVID-19 Vaccine Boosters; Public Health Surveillance; and Serving as an Endpoint for COVID-19 Vaccine Trials
Members of the Montana BioScience Alliance are encouraged to explore the Montana Rural Health Initiative—a significant statewide investment focused on rural care delivery, workforce development, telehealth, and applied clinical innovation. This program offers Alliance companies and research partners a rare chance to access non-dilutive funding, pilot technologies in real clinical settings, and build direct partnerships with Montana healthcare systems and community stakeholders. Just as importantly, it creates a pathway to demonstrate impact while advancing commercialization inside Montana. Backed by the administration of Greg Gianforte, the initiative aligns […]
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Members of the Montana BioScience Alliance are encouraged to explore the Montana Rural Health Initiative—a significant statewide investment focused on rural care delivery, workforce development, telehealth, and applied clinical innovation. This program offers Alliance companies and research partners a rare chance to access non-dilutive funding, pilot technologies in real clinical settings, and build direct partnerships with Montana healthcare systems and community stakeholders. Just as importantly, it creates a pathway to demonstrate impact while advancing commercialization inside Montana. Backed by the administration of Greg Gianforte, the initiative aligns […]
View the December BIOWire Newsletter now!